Product Code: A11271
The global carrier screening market was valued at $1,849.36 million in 2021 and is projected to reach $6,454.60 million by 2031, registering a CAGR of 13.8% from 2022 to 2031. Genetic testing is done for checking if people have genetic conditions or diseases that may be present in the family history prior to the occurrence of the symptoms or if people can pass on that genetic condition to their children. Genetic counselors help people decide what tests to get and understand the meaning of tests. It can be done on amniotic fluid through amniocentesis or the placenta through chorionic villus sampling in pregnant women. It can also be done on an embryo during in vitro fertilization (IVF). Usually, it takes a few weeks for test results to be ready. Some of the diseases for which genetic testing is preferred include cystic fibrosis, Tay-Sachs disease, sickle cell disease, down syndrome, spina bifida, turner syndrome, von Willebrand disease, albinism, and Duchenne muscular dystrophy.
An increase in the incidence of genetic diseases, a rise in the number of advanced product launches, and a surge in the availability & affordability of tests are the factors responsible for driving the growth of the market. Moreover, an increase in the number of biotechnology companies adopting strategies like acquisition is expected to notably contribute toward market growth. For instance, in August 2021, DiaSorin S.p.A. announced that it has completed the acquisition of Luminex Corporation for a price of $37.00 per share which corresponds to a total equity value of approximately $1.8 billion. Through the acquisition, DiaSorin has gained access to Luminex's multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the U.S. In addition, the global carrier screening market growth is largely driven by factors such as an increase in preference of carrier screening in genetic disorder fields, various initiatives & funding from government & private bodies for large-scale carrier screening projects and decline in cost of screening. The key market players in the global carrier screening market have opted for various strategies such as investments in R&D for advancement in carrier screening to strengthen their position in the market and sustain the competitive environment. However, the high cost associated with carrier screening and the dearth of skilled professionals restricts the market growth. Conversely, various technological advancements such as the development of next-generation sequencing (NGS) techniques for genetic disease screening and DNA sequencing are expected to provide lucrative opportunities for the growth of the market in the coming years. The increase in the R&D activities in the field of bioinformatics and biotechnology along with significant improvement in medical infrastructure is anticipated to increase the opportunities of the market.
The carrier screening market is segmented based on type, technology, end-user, and region. On the basis of type, the market is bifurcated into expanded carrier screening and targeted disease carrier screening. On the basis of technology, the market is classified into DNA sequencing, polymerase chain reaction, microarrays, and others. On the basis of end users, the market is classified into hospitals & clinics, reference laboratories, physician offices, and others. Region-wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major companies profiled in the report include Diasorin S.p.A (Luminex Corporation), Eurofins Scientific, Fulgent Genetics Inc., Illumina Inc., Invitae Corporation, Myriad Genetics Inc., Natera Inc., Opko Health Inc., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the carrier screening market analysis from 2021 to 2031 to identify the prevailing carrier screening market opportunities.
Market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
An in-depth analysis of the carrier screening market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes analysis of the regional as well as global carrier screening market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
- Expanded Carrier Screening
- Targeted Disease Carrier Screening
By Technology
- DNA Sequencing
- Polymerase Chain Reaction
- Microarrays
- Others
By End User
- Hospitals and clinics
- Reference Laboratories
- Physician Offices
- Others
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Fulgent Genetics Inc.
- Illumina Inc.
- Diasorin S.p.A.
- Natera Inc.
- Thermo Fisher Scientific Inc.
- Eurofins Scientific
- Myriad Genetics, Inc.
- Opko Health Inc
- Quest Diagnostics Inc.
- InVitae Corporation
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Market dynamics
- 3.4.1.Drivers
- 3.4.1.1. Increase in the prevalence of genetic disorders
- 3.4.1.2. Rise in the technological advancements
- 3.4.1.3. Rise in awareness for early disease diagnosis
- 3.4.2.Restraints
- 3.4.2.1. High cost associated with carrier screening and dearth of skilled professionals
- 3.4.3.Opportunities
- 3.4.3.1. Rise in the number of R&D investment by pharmaceutical companies
- 3.5.COVID-19 Impact Analysis on the market
CHAPTER 4: CARRIER SCREENING MARKET, BY TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2. Expanded Carrier Screening
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market share analysis by country
- 4.3. Targeted Disease Carrier Screening
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market share analysis by country
CHAPTER 5: CARRIER SCREENING MARKET, BY TECHNOLOGY
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2. DNA Sequencing
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market share analysis by country
- 5.3. Polymerase Chain Reaction
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market share analysis by country
- 5.4. Microarrays
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market share analysis by country
- 5.5. Others
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market share analysis by country
CHAPTER 6: CARRIER SCREENING MARKET, BY END USER
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2. Hospitals and clinics
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market share analysis by country
- 6.3. Reference Laboratories
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market share analysis by country
- 6.4. Physician Offices
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market share analysis by country
- 6.5. Others
- 6.5.1 Key market trends, growth factors and opportunities
- 6.5.2 Market size and forecast, by region
- 6.5.3 Market share analysis by country
CHAPTER 7: CARRIER SCREENING MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Type
- 7.2.3 North America Market size and forecast, by Technology
- 7.2.4 North America Market size and forecast, by End User
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Key market trends, growth factors and opportunities
- 7.2.5.1.2 Market size and forecast, by Type
- 7.2.5.1.3 Market size and forecast, by Technology
- 7.2.5.1.4 Market size and forecast, by End User
- 7.2.5.2 Canada
- 7.2.5.2.1 Key market trends, growth factors and opportunities
- 7.2.5.2.2 Market size and forecast, by Type
- 7.2.5.2.3 Market size and forecast, by Technology
- 7.2.5.2.4 Market size and forecast, by End User
- 7.2.5.3 Mexico
- 7.2.5.3.1 Key market trends, growth factors and opportunities
- 7.2.5.3.2 Market size and forecast, by Type
- 7.2.5.3.3 Market size and forecast, by Technology
- 7.2.5.3.4 Market size and forecast, by End User
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Type
- 7.3.3 Europe Market size and forecast, by Technology
- 7.3.4 Europe Market size and forecast, by End User
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Key market trends, growth factors and opportunities
- 7.3.5.1.2 Market size and forecast, by Type
- 7.3.5.1.3 Market size and forecast, by Technology
- 7.3.5.1.4 Market size and forecast, by End User
- 7.3.5.2 France
- 7.3.5.2.1 Key market trends, growth factors and opportunities
- 7.3.5.2.2 Market size and forecast, by Type
- 7.3.5.2.3 Market size and forecast, by Technology
- 7.3.5.2.4 Market size and forecast, by End User
- 7.3.5.3 UK
- 7.3.5.3.1 Key market trends, growth factors and opportunities
- 7.3.5.3.2 Market size and forecast, by Type
- 7.3.5.3.3 Market size and forecast, by Technology
- 7.3.5.3.4 Market size and forecast, by End User
- 7.3.5.4 Italy
- 7.3.5.4.1 Key market trends, growth factors and opportunities
- 7.3.5.4.2 Market size and forecast, by Type
- 7.3.5.4.3 Market size and forecast, by Technology
- 7.3.5.4.4 Market size and forecast, by End User
- 7.3.5.5 Spain
- 7.3.5.5.1 Key market trends, growth factors and opportunities
- 7.3.5.5.2 Market size and forecast, by Type
- 7.3.5.5.3 Market size and forecast, by Technology
- 7.3.5.5.4 Market size and forecast, by End User
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Key market trends, growth factors and opportunities
- 7.3.5.6.2 Market size and forecast, by Type
- 7.3.5.6.3 Market size and forecast, by Technology
- 7.3.5.6.4 Market size and forecast, by End User
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Technology
- 7.4.4 Asia-Pacific Market size and forecast, by End User
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Key market trends, growth factors and opportunities
- 7.4.5.1.2 Market size and forecast, by Type
- 7.4.5.1.3 Market size and forecast, by Technology
- 7.4.5.1.4 Market size and forecast, by End User
- 7.4.5.2 China
- 7.4.5.2.1 Key market trends, growth factors and opportunities
- 7.4.5.2.2 Market size and forecast, by Type
- 7.4.5.2.3 Market size and forecast, by Technology
- 7.4.5.2.4 Market size and forecast, by End User
- 7.4.5.3 Australia
- 7.4.5.3.1 Key market trends, growth factors and opportunities
- 7.4.5.3.2 Market size and forecast, by Type
- 7.4.5.3.3 Market size and forecast, by Technology
- 7.4.5.3.4 Market size and forecast, by End User
- 7.4.5.4 India
- 7.4.5.4.1 Key market trends, growth factors and opportunities
- 7.4.5.4.2 Market size and forecast, by Type
- 7.4.5.4.3 Market size and forecast, by Technology
- 7.4.5.4.4 Market size and forecast, by End User
- 7.4.5.5 South Korea
- 7.4.5.5.1 Key market trends, growth factors and opportunities
- 7.4.5.5.2 Market size and forecast, by Type
- 7.4.5.5.3 Market size and forecast, by Technology
- 7.4.5.5.4 Market size and forecast, by End User
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Key market trends, growth factors and opportunities
- 7.4.5.6.2 Market size and forecast, by Type
- 7.4.5.6.3 Market size and forecast, by Technology
- 7.4.5.6.4 Market size and forecast, by End User
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Type
- 7.5.3 LAMEA Market size and forecast, by Technology
- 7.5.4 LAMEA Market size and forecast, by End User
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Key market trends, growth factors and opportunities
- 7.5.5.1.2 Market size and forecast, by Type
- 7.5.5.1.3 Market size and forecast, by Technology
- 7.5.5.1.4 Market size and forecast, by End User
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Key market trends, growth factors and opportunities
- 7.5.5.2.2 Market size and forecast, by Type
- 7.5.5.2.3 Market size and forecast, by Technology
- 7.5.5.2.4 Market size and forecast, by End User
- 7.5.5.3 South Africa
- 7.5.5.3.1 Key market trends, growth factors and opportunities
- 7.5.5.3.2 Market size and forecast, by Type
- 7.5.5.3.3 Market size and forecast, by Technology
- 7.5.5.3.4 Market size and forecast, by End User
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Key market trends, growth factors and opportunities
- 7.5.5.4.2 Market size and forecast, by Type
- 7.5.5.4.3 Market size and forecast, by Technology
- 7.5.5.4.4 Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
- 9.1 Fulgent Genetics Inc.
- 9.1.1 Company overview
- 9.1.2 Key Executives
- 9.1.3 Company snapshot
- 9.1.4 Operating business segments
- 9.1.5 Product portfolio
- 9.1.6 Business performance
- 9.1.7 Key strategic moves and developments
- 9.2 Illumina Inc.
- 9.2.1 Company overview
- 9.2.2 Key Executives
- 9.2.3 Company snapshot
- 9.2.4 Operating business segments
- 9.2.5 Product portfolio
- 9.2.6 Business performance
- 9.2.7 Key strategic moves and developments
- 9.3 Diasorin S.p.A.
- 9.3.1 Company overview
- 9.3.2 Key Executives
- 9.3.3 Company snapshot
- 9.3.4 Operating business segments
- 9.3.5 Product portfolio
- 9.3.6 Business performance
- 9.3.7 Key strategic moves and developments
- 9.4 Natera Inc.
- 9.4.1 Company overview
- 9.4.2 Key Executives
- 9.4.3 Company snapshot
- 9.4.4 Operating business segments
- 9.4.5 Product portfolio
- 9.4.6 Business performance
- 9.4.7 Key strategic moves and developments
- 9.5 Thermo Fisher Scientific Inc.
- 9.5.1 Company overview
- 9.5.2 Key Executives
- 9.5.3 Company snapshot
- 9.5.4 Operating business segments
- 9.5.5 Product portfolio
- 9.5.6 Business performance
- 9.5.7 Key strategic moves and developments
- 9.6 Eurofins Scientific
- 9.6.1 Company overview
- 9.6.2 Key Executives
- 9.6.3 Company snapshot
- 9.6.4 Operating business segments
- 9.6.5 Product portfolio
- 9.6.6 Business performance
- 9.6.7 Key strategic moves and developments
- 9.7 Myriad Genetics, Inc.
- 9.7.1 Company overview
- 9.7.2 Key Executives
- 9.7.3 Company snapshot
- 9.7.4 Operating business segments
- 9.7.5 Product portfolio
- 9.7.6 Business performance
- 9.7.7 Key strategic moves and developments
- 9.8 Opko Health Inc
- 9.8.1 Company overview
- 9.8.2 Key Executives
- 9.8.3 Company snapshot
- 9.8.4 Operating business segments
- 9.8.5 Product portfolio
- 9.8.6 Business performance
- 9.8.7 Key strategic moves and developments
- 9.9 Quest Diagnostics Inc.
- 9.9.1 Company overview
- 9.9.2 Key Executives
- 9.9.3 Company snapshot
- 9.9.4 Operating business segments
- 9.9.5 Product portfolio
- 9.9.6 Business performance
- 9.9.7 Key strategic moves and developments
- 9.10 InVitae Corporation
- 9.10.1 Company overview
- 9.10.2 Key Executives
- 9.10.3 Company snapshot
- 9.10.4 Operating business segments
- 9.10.5 Product portfolio
- 9.10.6 Business performance
- 9.10.7 Key strategic moves and developments